Biogen Q1 Beat Lifts Sentiment, But Structural Transition Still Unresolved

What happened

Biogen's upbeat Q1 earnings beat market expectations, prompting several analysts to raise their price targets and fueling a positive near-term reaction. The stronger-than-expected results were driven by continued momentum in rare-disease drugs like Skyclarys and Zurzuvae, as well as solid Leqembi demand, which helped offset ongoing declines in multiple sclerosis revenue. However, our full review of Biogen's filings confirms that the company's fundamental transition remains incomplete, with MS erosion persisting and business-development charges pressuring earnings. The Q1 beat is consistent with our base-case scenario of revenue stabilization, but it does not yet signal a clear growth inflection that would justify a higher multiple. Investors should view the rally as sentiment-driven and wait for further evidence from 2026 guidance before adjusting their thesis.

Implication

While the Q1 earnings beat and analyst upgrades are encouraging, they align with our base-case assumption that Biogen can stabilize revenue through 2025. The stock's move toward our trim above $210 limits further upside from here, and we continue to see a favorable risk/reward in the $165 area. Long-term investors should focus on Leqembi adoption, rare-disease growth, and the 2026 outlook rather than chasing the immediate rally. Our WAIT rating remains unchanged.

Thesis delta

No material shift from our existing thesis; the Q1 beat is in line with our base-case forecast of gradual revenue stabilization as launch products and rare-disease growth offset MS declines. However, the stock's approach to our trim level ($210) reduces the near-term upside, reinforcing our WAIT stance until clearer growth signals emerge from 2026 guidance. The fundamental story of a portfolio in transition remains intact, with key risks and catalysts unchanged.